Corbus Pharmaceuticals
CRBP · Nasdaq · United States
Share price · CRBP
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when CRBP's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 17 Nov 2026-10.8%
- 12 Nov 2026-14.7%
- Day beforeEarnings date (period ending 2026-09-30)
- 10 Nov 2026+11.6%
- 9 Nov 2026+14.7%
Nothing announced by CRBP that day or the session before.
- 5 Nov 2026-19.9%
- 4 Nov 2026-7.8%
Nothing announced by CRBP that day or the session before.
- 15 Sep 2026-14.4%
- 9 Sep 2026-16.4%
Nothing announced by CRBP that day or the session before.
- 26 May 2026-30.3%
- 21 May 2026+18.3%
Share of unusual movement by asset
For each asset, the share of CRBP's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Nectin-4Antibody–drug conjugate | Cervical CancerBladder / Urothelial Cancer Urothelial Carcinoma | |
| Phase 1 | CB1 receptorSmall molecule | Obesity |
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (3)
2028 (2)
2029 (1)
June 2029 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (17)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $34M | $30M+ $85M short-term inv. | $38M-$21M operating cash flow | report ↗ |
View 16 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $31M | $23M+ $95M short-term inv. | $35M-$30M operating cash flow | report ↗ |
| 2026-Q1 | — | $20M | $26M+ $113M short-term inv. | $23M-$26M operating cash flow | report ↗ |
| 2025-Q3 | — | $21M | $27M+ $77M short-term inv. | $23M-$16M operating cash flow | report ↗ |
| 2025-Q2 | — | $15M | $20M+ $97M short-term inv. | $18M-$17M operating cash flow | report ↗ |
| 2025-Q1 | — | $16M | $19M+ $114M short-term inv. | $17M-$16M operating cash flow | report ↗ |
| 2024-Q3 | — | $11M | $19M+ $140M short-term inv. | $14M-$14M operating cash flow | report ↗ |
| 2024-Q2 | — | $6.9M | $24M+ $123M short-term inv. | $10M-$8.9M operating cash flow | report ↗ |
| 2024-Q1 | — | $5.8M | $14M+ $106M short-term inv. | $6.9M-$8.0M operating cash flow | report ↗ |
| 2023-Q3 | — | $6.5M | $11M+ $17M short-term inv. | $10M-$7.2M operating cash flow | report ↗ |
| 2023-Q2 | — | $4.3M | $8.3M+ $28M short-term inv. | $8.8M-$7.8M operating cash flow | report ↗ |
| 2023-Q1 | — | $13M | $7.3M+ $37M short-term inv. | $18M-$15M operating cash flow | report ↗ |
| 2022-Q3 | $0 | $4.1M | $12M+ $54M short-term inv. | $8.8M-$7.3M operating cash flow | report ↗ |
| 2022-Q2 | — | $2.5M | $26M+ $48M short-term inv. | $13M-$12M operating cash flow | report ↗ |
| 2022-Q1 | $0 | $3.3M | $57M+ $29M short-term inv. | $9.4M-$11M operating cash flow | report ↗ |
| 2021-Q4 | — | $0.4M | $25M+ $73M short-term inv. | —-$9.7M operating cash flow | report ↗ |
| 2021-Q3 | $0.1M | $8.7M | $37M+ $70M short-term inv. | $2.2M$0.9M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $70M | $28M+ $135M short-term inv. | $20M-$64M operating cash flow | report ↗ |
Corbus Pharmaceuticals reported no revenue for fiscal year 2025. Research and development spending was $70.1M, up 117.6% YoY, while cash and equivalents stood at $28.49M. The company reported a net loss of $78.54M for the full year.
Management guided that existing cash is expected to fund operations into 2028. CRB-701 demonstrated encouraging Phase 1/2 efficacy data at ESMO 2025 in HNSCC, cervical, and bladder cancers, with monotherapy data expected in mid-2026 and a Keytruda combination readout in Q4 2026. CRB-913 showed 2.9% placebo-adjusted weight loss at 14 days with a favorable gastrointestinal safety profile, and the 12-week CANYON-1 obesity study (n=240) is scheduled to complete in summer 2026. The CRB-601 program was deprioritized, and a $75 million public offering closed in Q4 2025.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $32M | $17M+ $132M short-term inv. | $10M-$42M operating cash flow | report ↗ |
| 2023-FY | — | $31M | $14M+ $7.2M short-term inv. | $11M-$36M operating cash flow | report ↗ |
| 2022-FY | $0 | $16M | $17M+ $42M short-term inv. | $11M-$38M operating cash flow | report ↗ |
| 2021-FY | $0.9M | $36M | $25M+ $73M short-term inv. | $11M-$48M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 3 purchases ($126K), 14 sales ($2.7M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-29 | Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Chen Bihua · Former 10% Owner; Former 10% Owner; Former 10% Owner | Open-market sale | 425,000 | $4.10 | $1.7M | Form 4 |
| 2026-09-14 | Ben Yong · director | Open-market sale | 2,000 | $7.84 | $16K | Form 4 |
| 2026-08-16 | Nicacio Leonardo Viana · Chief Medical Officer | Award / grant | 58,333 | — | — | Form 4 |
| 2026-08-16 | Nicacio Leonardo Viana · Chief Medical Officer | Award / grant (derivative) | 191,676 | — | — | Form 4 |
| 2026-08-11 | Saxena Nishant C · Chief Business Officer | Open-market purchase | 2,600 | $9.63 | $25K | Form 4 |
| 2026-08-07 | Moran Sean F. · Chief Financial Officer | Open-market sale | 12,000 | $10.08 | $121K | Form 4 |
| 2026-08-07 | Cohen Yuval · director, Chief Executive Officer | Open-market sale | 17,000 | $10.08 | $171K | Form 4 |
| 2026-06-10 | Jenkins John Kenneth · director | Open-market sale | 4,800 | $7.91 | $38K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 105 reporting institutions held 12.8M shares ($119.1M, 62.3% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Cormorant Asset Management, LP | 2,344,971 | $22.0M |
| 2 | ORBIMED ADVISORS LLC | 1,737,287 | $16.3M |
| 3 | Aberdeen Group plc | 1,321,750 | $12.4M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 734,106 | $6.9M |
| 5 | CITADEL ADVISORS LLC | 727,060 | $6.8M |
| 6 | Prosight Management, LP | 697,108 | $6.5M |
| 7 | DIADEMA PARTNERS LP | 439,957 | $4.1M |
| 8 | Stonepine Capital Management, LLC | 383,462 | $3.6M |
| 9 | ARMISTICE CAPITAL, LLC | 364,000 | $3.4M |
| 10 | RENAISSANCE TECHNOLOGIES LLC | 346,998 | $3.3M |
| 11 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 333,415 | $3.1M |
| 12 | ADAR1 Capital Management, LLC | 331,781 | $3.1M |
| 13 | BlackRock, Inc. | 271,636 | $2.6M |
| 14 | Exome Asset Management LLC | 234,136 | $2.2M |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 187,029 | $1.8M |